World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
63622
World Ranking
3698
National Ranking
2037

Robert A. Figlin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert A. Figlin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 592 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert A. Figlin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert A. Figlin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 120 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert A. Figlin is affiliated with Cedars-Sinai Medical Center in the United States and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research primarily focuses on oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and economic and financial impacts of cancer.

Their work spans multiple main topics, including:

  • Renal cell carcinoma treatment
  • Renal and related cancers
  • Cancer genomics and diagnostics
  • Cancer immunotherapy and biomarkers
  • Prostate cancer treatment and research
  • Pancreatic and hepatic oncology research
  • Economic and financial impacts of cancer

Recent impactful papers authored or coauthored by Robert A. Figlin include:

  • "Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma," 2023, Journal of Clinical Oncology
  • "Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma," 2022, JAMA Oncology
  • "Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study," 2023, The Lancet Oncology
  • "COVID-19 and androgen-targeted therapy for prostate cancer patients," 2020, Endocrine Related Cancer
  • "Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma," 2020, Clinical Cancer Research

Frequent coauthors collaborating with Robert A. Figlin include William J. Gradishar, New York, Tanios Bekaii-Saab, Eric J. Sherman, and Malignancies Landgren.

Their publications appear predominantly in venues such as:

  • ONCOLOGY
  • Journal of Clinical Oncology
  • Kidney Cancer Journal
  • The Lancet Oncology
  • OncoTargets and Therapy

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

    Gary Hudes;Michael Carducci;Piotr Tomczak;Janice Dutcher

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;M. Dror Michaelson;Bruce G. Redman;Gary R. Hudes

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

    Nicolette K Janzen;Hyung L Kim;Robert A Figlin;Arie S Belldegrun

  • Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System

    Amnon Zisman;Allan J. Pantuck;Fredrick Dorey;Jonathan W. Said

  • Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

    Jean Jacques Patard;Emmanuelle Leray;Nathalie Rioux-Leclercq;Luca Cindolo

  • Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma

    Amnon Zisman;Allan J. Pantuck;Jeffery Wieder;Debby H. Chao

  • Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy

    Matthew H.T. Bui;David Seligson;Ken ryu Han;Allan J. Pantuck

  • SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY FOR ALL T1 TUMORS BASED ON AN INTERNATIONAL MULTICENTER EXPERIENCE

    Jean-Jacques Patard;Oleg Shvarts;John S. Lam;Allan J. Pantuck

  • Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

    Hong Xin;Chunyan Zhang;Andreas Herrmann;Yan Du

  • Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

    Brian I. Rini;Darrel P. Cohen;Dongrui R. Lu;Isan Chen

  • Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma

    Matthew H. T. Bui;David Seligson;Ken-ryu Han;Allan J. Pantuck

  • NCCN clinical practice guidelines in oncology: kidney cancer.

    Robert J Motzer;Neeraj Agarwal;Clair Beard;Graeme B Bolger

  • Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.

    Ke-Hung Tsui;Oleg Shvarts;Robert B. Smith;Robert A. Figlin

  • Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

    John S. Lam;Oleg Shvarts;John T. Leppert;Robert A. Figlin

  • Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study

    Jean Jacques Patard;Hyung L. Kim;John S. Lam;Frederick J. Dorey

  • An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

    Christopher Wood;Pramod Srivastava;Ronald Bukowski;Louis Lacombe

  • RENAL CELL CARCINOMA: PROGNOSTIC SIGNIFICANCE OF INCIDENTALLY DETECTED TUMORS

    Ke-Hung Tsui;Oleg Shvarts;Robert B. Smith;Robert Figlin

Frequent Co-Authors

Arie S. Belldegrun
Arie S. Belldegrun University of California, Los Angeles
Allan J. Pantuck
Allan J. Pantuck University of California, Los Angeles
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Thomas E. Hutson
Thomas E. Hutson Texas Oncology
Christopher G. Wood
Christopher G. Wood The University of Texas MD Anderson Cancer Center
Jonathan W. Said
Jonathan W. Said University of California, Los Angeles
Frederick J. Dorey
Frederick J. Dorey University of California, Los Angeles
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Ronald M. Bukowski
Ronald M. Bukowski Cleveland Clinic
Hua Yu
Hua Yu City Of Hope National Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in healthcare careers beyond traditional Medicine, there are several flexible online degrees to explore. These online programs make it possible to start or advance your healthcare career from anywhere in the USA.

For registered nurses seeking to further their education, the cheapest online bsn programs offer affordable pathways to a Bachelor of Science in Nursing. If you want to pivot into nursing from a different field, direct msn programs online are designed for non-nursing graduates who are ready to transition quickly.

Those just starting out can consider online adn programs that provide streamlined entry into the nursing profession. Meanwhile, careers like medical billing and coding are experiencing rapid growth and can be started via an accredited certificate or degree. Interested in this pathway? Discover programs that offer online medical billing and coding with financial aid.

These online options help make healthcare education more accessible, providing a variety of career paths for future professionals.

Best Scientists Citing Robert A. Figlin

Trending Scientists